IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Quantitative analysis updated February 24, 2026. Data-driven, not AI-generated.
Based on our 6-factor quantitative model, GILEAD SCIENCES, INC. receives a Buy rating with a composite score of 67/100, ranking #203 out of 7,333 stocks in our coverage universe.
The stock scores particularly well on Stability (89th percentile).
On a valuation basis, GILD trades at a 49% discount to its sector median P/E, suggesting the market may be underpricing the company's earnings power.
Our composite score is built from six academically-proven factors, each measured as a percentile rank across our entire coverage universe of 7,333 stocks. Higher percentile scores indicate stronger relative performance on that dimension.
GILEAD SCIENCES, INC. shows solid profitability metrics that exceed the market median. Margins and returns on capital are healthy, suggesting a well-managed business with reasonable competitive positioning.
ROE: 53.7% · Gross Margin: 79.8% · Op. Margin: 42.8% · Net Margin: 39.3%
GILEAD SCIENCES, INC. trades at a significant discount to intrinsic value based on multiple valuation frameworks. Price-to-earnings, price-to-book, and EV/EBITDA ratios all suggest the market is underpricing the company's fundamentals.
P/E: 11.3 · P/B: 6.4 · P/S: 4.4 · EV/EBITDA: 7.5
GILEAD SCIENCES, INC. shows positive price trends that exceed the market average. Recent performance has been favorable, though not in the top tier of momentum-driven stocks.
Momentum percentile rank indicates price trend strength across 3, 6, and 12 month horizons.
GILEAD SCIENCES, INC. invests at a pace roughly in line with the market average. Capital deployment is neither overly aggressive nor conservative, maintaining a neutral posture on the investment factor.
Revenue Growth: 3.0% · D/E: 116.0%
GILEAD SCIENCES, INC. demonstrates notably low price volatility and consistent return patterns. Low-volatility stocks have historically delivered risk-adjusted returns that exceed theoretical predictions (Baker, Bradley & Wurgler, 2011).
Beta: 0.38
GILEAD SCIENCES, INC. has short interest levels near the market median. The amount of shares sold short is not unusual and does not represent a significant signal in either direction.
Short interest as a percentage of float, relative to the market universe.
GILEAD SCIENCES, INC. appears undervalued relative to its sector, trading at a 49% discount to the sector median P/E of 22.3x. This discount may represent an attractive entry point for value-oriented investors, though further analysis of growth expectations is warranted.
| Metric | GILD | Manufacturing Median | vs. Sector |
|---|---|---|---|
| P/E Ratio | 11.3x | 22.3x | -49% |
| P/B Ratio | 6.4x | 2.6x | +143% |
| P/S Ratio | 4.4x | 2.4x | +82% |
| EV/EBITDA | 7.5x | 11.5x | -34% |
This stock exhibits below-average risk characteristics including low volatility, manageable debt, and stable return patterns. It may serve as a defensive holding in a diversified portfolio.
We'll email you when stocks you follow change their composite rating.
Comprehensive fundamental data for GILEAD SCIENCES, INC. compared against Manufacturing sector medians. All data sourced from SEC filings and updated daily.
| Metric | GILD | Manufacturing Median |
|---|---|---|
| Market Cap | $137.73B | -- |
| P/E Ratio | 11.3x | 22.3x |
| P/B Ratio | 6.4x | 2.6x |
| P/S Ratio | 4.4x | 2.4x |
| EV/EBITDA | 7.5x | 11.5x |
| Return on Equity | 53.7% | -2.5% |
| Return on Assets | 20.2% | -0.1% |
| Gross Margin | 79.8% | 42.5% |
| Operating Margin | 42.8% | 1.3% |
| Net Margin | 39.3% | -0.2% |
| Revenue Growth | 3.0% | 5.9% |
| Debt / Equity | 116.0% | 0.2% |
| Dividend Yield | 2.8% | 0.0% |
| Beta | 0.38 | -- |
GILEAD SCIENCES, INC. earns a Buy rating from our quantitative model, supported by strong factor scores that place it in the top tier of our coverage universe. The combination of solid quality metrics, favorable valuation, and positive momentum creates a compelling investment case. Investors seeking exposure to the Manufacturing sector should consider GILD as a high-conviction opportunity, while maintaining appropriate position sizing and portfolio diversification.
Disclaimer: This analysis is based on quantitative factor models and does not constitute personalized investment advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.